CVE-2026-52866

HIGHCVSS 7.1/10EPSS 0.22%

Last modified

CVE-2026-52866 is a high-severity vulnerability rated 7.1/10 on the CVSS scale. An attacker within BLE communication range can monopolize the device's only available BLE connection slot, preventing legitimate users or applications from establishing a connection.. EPSS estimates a 0.22% chance of exploitation in the next 30 days.

Description

An attacker within BLE communication range can monopolize the device's only available BLE connection slot, preventing legitimate users or applications from establishing a connection.

Metrics

CVSS 3.1
6.5/10

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

CVSS 4.0
7.1/10

CVSS:4.0/AV:A/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

EPSS Probability
0.22%

12.6th percentile

Probability of exploitation in the next 30 days. Learn more

Weakness Enumeration

Affected Software

Source: CNA advisory (CVE.org). NVD analysis pending.

VendorProductVersions
Apollo PharmacyBlood Glucose Monitoring System (Model No. APG-01 BT)0x0110_v1.1.0

References

Timeline

Published
Last Modified
Status
Awaiting Analysis

Frequently Asked Questions

What is CVE-2026-52866?
An attacker within BLE communication range can monopolize the device's only available BLE connection slot, preventing legitimate users or applications from establishing a connection.
How severe is CVE-2026-52866?
CVE-2026-52866 has a CVSS score of 7.1/10 (HIGH severity). The EPSS model estimates a 0.22% probability of exploitation in the next 30 days.
How do I fix CVE-2026-52866?
Check the vendor references and advisories linked above for patched versions and mitigation guidance. You can also run a Strix scan to test if your systems are affected.

How Strix Helps

Related CVEs from 2026

Are you affected by CVE-2026-52866?

Run a free Strix scan to check your systems for this vulnerability.

Scan your code now

Source: NVD / NIST